Recommended loading dose: 200 mg every 8 hr for 1st 48 hr. Maintenance dose: 200 mg once daily starting 12-24 hr after last loading dose. Infusion To be reconstituted & then further diluted to a conc corresponding to approx 0.8 mg/mL isavuconazole prior to administration by IV infusion over a min of 1 hr.
Hypersensitivity to other azole antifungals. Discontinue use if severe cutaneous ARs eg, SJS develop; infusion-related reactions occur. Avoid co-administration w/ mild CYP3A4/5 inducers eg, aprepitant, prednisone, pioglitazone. Concomitant use w/ other medicinal products decreasing QT interval eg, rufinamide; strong CYP3A4/5 inhibitors; CYP3A4 substrates eg, tacrolimus, sirolimus or ciclosporin; CYP2B6 substrates eg, cyclophosphamide; P-gp substrates eg, digoxin, colchicine, dabigatran etexilate. Monitor hepatic enzymes as clinically indicated. Moderate potential to influence the ability to drive & use machines. Not recommended in severe hepatic impairment (Child-Pugh C). Not recommended in women of childbearing potential not using contraception. Must not be used during pregnancy except in patients w/ severe or potentially life-threatening fungal infections. Breast-feeding should be discontinued during treatment. Childn <18 yr. Elderly.
Sign Out
